HCV, HIV AND HBV rapid test diagnosis in non-clinical outreach settings can be as accurate as conventional laboratory tests

Author:

Muñoz-Chimeno Milagros,Valencia Jorge,Rodriguez-Recio Alvaro,Cuevas Guillermo,Garcia-Lugo Alejandra,Manzano Samuel,Rodriguez-Paredes Vanessa,Fernandez Beatriz,Morago Lucía,Casado Concepción,Avellón Ana,Ryan Pablo

Abstract

AbstractPoint of care rapid diagnostic tests (POC-RDT) for Hepatitis C virus (HCV), Human Immunodeficiency virus (HIV) and Hepatitis B virus (HBV), are ideal for screening in non-clinical outreach settings as they can provide immediate results and facilitate diagnosis, allowing high risk population screening. The aim of this study was to compare POC-RDT with laboratory conventional tests. A total of 301 vulnerable evaluable subjects (drug users, migrants and homeless population) were recruited at a mobile screening unit in outreach settings in Madrid. Fingerprick whole blood capillary samples were tested using the SD BIOLINE HCV POC-RDT, Determine HIV Early Detect and Determine HBsAg 2, and the results were assessed against the LIAISON XL HCV, HIV and Murex-HBsAg-Quant, reference assays, respectively. The feasibility and user satisfaction of the POC-RDT were evaluated through a questionnaire. The resolved sensitivity and resolved specificity and their 95% confidence intervals (95% CI) were as follows, respectively: SD-BIOLINE-HCV: 98.8% (95% CI 93.4, 100.0) and 100.0% (95% CI 98.3, 100.0); Determine HIV Early Detect: 100% (95% CI 85.2, 100.0) and 100% (95% CI 98.7, 100); and Determine HBsAg 2: 66.7% (95% CI 9.4, 99.2) and 100.0% (95% CI 98.7, 100.0). As expected, the number of subjects with a confirmed positive result for HBsAg was very low (n = 4). Therefore, the analytical sensitivity has been evaluated in addition: The Determine HBsAg 2 test demonstrated 100% sensitivity for standard concentrations ≥ 0.125 IU/mL. The subject questionnaire yielded positive feedback for most subjects. The POC-RDT fingerprick blood collection method was well received, and the tests demonstrated a comparable clinical performance with conventional tests in outreach settings and vulnerable high-risk populations.

Funder

This study was supported by the research contract MVP128/21 ISCIII-Abbott

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference31 articles.

1. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (2021).

2. WHO. https://www.who.int/news-room/fact-sheets/detail/hiv-aids (2021).

3. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (2021).

4. Grebely, J., Dore, G. J., Morin, S., Rockstroh, J. K. & Klein, M. B. Elimination of HCV as a public health concern among people who inject drugs by 2030: What will it take to get there?. J. Int. AIDS Soc. 20, 22146. https://doi.org/10.7448/IAS.20.1.22146 (2017).

5. WHO. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-242016.246106-eng.pdf (2017).

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3